Genetic Testing for Managing Dyslipidemia
Nov 16, 2020 | Chloe Duvall, MD; Esra Gucuk Ipek, MD; Emily Brown, MS; Roger S. Blumenthal, MD, FACC; Thorsten Leucker, MD, PhD, FACC
Expert Analysis
The link between elevated serum cholesterol, triglyceride, and lipoprotein levels and increased atherosclerotic (ASCVD) risk is well established.
Clinical Topics: Arrhythmias and Clinical EP, Diabetes and Cardiometabolic Disease, Dyslipidemia, Atherosclerotic Disease (CAD/PAD), Genetic Arrhythmic Conditions, Lipid Metabolism, Nonstatins, Novel Agents, Primary Hyperlipidemia
Keywords: Dyslipidemias, Hyperlipoproteinemia Type II, Apolipoprotein B-100, Genetic Counseling, Cholesterol, LDL, Ursidae, PCSK9 protein, human, Proprotein Convertase 9, Coronary Artery Disease, Apolipoproteins B, Hyperlipidemias, Homozygote, Heterozygote